BRPI0413742B8 - composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante - Google Patents

composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante

Info

Publication number
BRPI0413742B8
BRPI0413742B8 BRPI0413742A BRPI0413742A BRPI0413742B8 BR PI0413742 B8 BRPI0413742 B8 BR PI0413742B8 BR PI0413742 A BRPI0413742 A BR PI0413742A BR PI0413742 A BRPI0413742 A BR PI0413742A BR PI0413742 B8 BRPI0413742 B8 BR PI0413742B8
Authority
BR
Brazil
Prior art keywords
antioxidant compound
methods
oxidative stress
compounds
synthesis
Prior art date
Application number
BRPI0413742A
Other languages
English (en)
Inventor
Martin Taylor Kenneth
Smith Robin
Original Assignee
Antipodean Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antipodean Pharmaceuticals Inc filed Critical Antipodean Pharmaceuticals Inc
Publication of BRPI0413742A publication Critical patent/BRPI0413742A/pt
Publication of BRPI0413742B1 publication Critical patent/BRPI0413742B1/pt
Publication of BRPI0413742B8 publication Critical patent/BRPI0413742B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

derivados de mitoquinona usados como antioxidantes mitocondrialmente alvejados esta invenção está relacionada a compostos antioxidantes anfifílicos farmaceuticamente aceitáveis, composições e formas de dosagens compreendendo os referidos compostos, e métodos e usos baseados nos referidos compostos. os compostos exemplificados são todos derivados de mitoquinona, sendo derivados de metoxifenil alquil trifenilfosfônio ou metóxi dioxociclohexadieno alquil trifenilfosfônio. os compostos, composições, formas de dosagem, usos e métodos sejam úteis, por exemplo, no tratamento de doenças ou condições associadas com estresse oxidativo.
BRPI0413742A 2003-08-22 2004-08-23 composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante BRPI0413742B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ52780003 2003-08-22
NZ527800 2003-08-22
NZ52915303 2003-10-23
NZ529153 2003-10-23
NZ53355604 2004-06-14
NZ533556 2004-06-14
PCT/NZ2004/000196 WO2005019232A1 (en) 2003-08-22 2004-08-23 Mitoquinone derivatives used as mitochondrially targeted antioxidants

Publications (3)

Publication Number Publication Date
BRPI0413742A BRPI0413742A (pt) 2006-10-24
BRPI0413742B1 BRPI0413742B1 (pt) 2019-05-21
BRPI0413742B8 true BRPI0413742B8 (pt) 2021-05-25

Family

ID=34222195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413742A BRPI0413742B8 (pt) 2003-08-22 2004-08-23 composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante

Country Status (8)

Country Link
EP (1) EP1664069B8 (pt)
KR (1) KR100974202B1 (pt)
AU (1) AU2004266988B2 (pt)
BR (1) BRPI0413742B8 (pt)
CA (1) CA2536546C (pt)
NO (1) NO337925B1 (pt)
RU (1) RU2487880C2 (pt)
WO (2) WO2005019232A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
CN1997403A (zh) * 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
SI1933821T1 (sl) 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009111846A1 (en) * 2008-03-14 2009-09-17 Stephen John Ralph Mitochondrially delivered anti-cancer compounds
KR101715631B1 (ko) * 2008-04-01 2017-03-13 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
MX2011003361A (es) * 2008-10-06 2011-07-28 Elizabeth Arden Internat S A R L Tratamientos para la piel que contienen derivados de idebenona sustituidos con acido carboxilico, y metodos de preparacion y uso de los mismos.
WO2011108946A1 (en) * 2010-03-04 2011-09-09 Androgenix Ltd Methods for improving sperm functionality
RU2527519C2 (ru) * 2010-06-24 2014-09-10 Общество С Ограниченной Ответственностью "Митотех" Мягкие катионные митохондриальные разобщители
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
US10806703B2 (en) 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2019104115A1 (en) 2017-11-24 2019-05-31 Lunella Biotech, Inc. Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
US20220162240A1 (en) * 2019-01-25 2022-05-26 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
DE102019218241A1 (de) * 2019-11-26 2021-05-27 Beiersdorf Ag Wirkstoffkombinationen aus Ubichinol und Carrageenan und kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
GB2610815A (en) * 2021-09-14 2023-03-22 Mitorx Therapeutics Ltd Compounds
CN116969982A (zh) * 2023-07-06 2023-10-31 湖北科技学院 一种基于bodipy的线粒体靶向抗氧化剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE296305T1 (de) * 1997-11-25 2005-06-15 Antipodean Biotechnology Ltd Antioxidantien mit spezifischer wirkung auf mitochondrien
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)

Also Published As

Publication number Publication date
BRPI0413742A (pt) 2006-10-24
WO2005019233A1 (en) 2005-03-03
NO337925B1 (no) 2016-07-11
NO20060977L (no) 2006-05-19
KR100974202B1 (ko) 2010-08-06
CA2536546A1 (en) 2005-03-03
CA2536546C (en) 2012-10-02
EP1664069B1 (en) 2015-04-08
EP1664069A4 (en) 2009-09-30
RU2487880C2 (ru) 2013-07-20
BRPI0413742B1 (pt) 2019-05-21
AU2004266988B2 (en) 2011-05-26
WO2005019232A1 (en) 2005-03-03
EP1664069B8 (en) 2015-07-01
KR20070018766A (ko) 2007-02-14
EP1664069A1 (en) 2006-06-07
AU2004266988A1 (en) 2005-03-03
RU2006109020A (ru) 2007-09-27

Similar Documents

Publication Publication Date Title
BRPI0413742B8 (pt) composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
SG145715A1 (en) Mitoquinone derivatives used as mitochondrially targeted antioxidants
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
UY30748A1 (es) Compuesto0s novedosos
UY27740A1 (es) Nuevos compuestos
BRPI0507198A (pt) derivados de bisariluréia
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY28572A1 (es) Compuestos novedosos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
UY28144A1 (es) Agentes terapéuticos
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
UY28366A1 (es) Compuestos químicos
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2844 DE 08/07/2025 POR TER SIDO INDEVIDA.